Department of Haematology, Oncology and Internal Medicine, The Medical University of Warsaw, Warsaw, Poland.
Acta Haematol. 2013;130(3):169-71. doi: 10.1159/000348414. Epub 2013 May 28.
The addition of rituximab to standard chemotherapy has improved the results of the treatment of B cell non-Hodgkin's lymphomas. Under specific circumstances, it can be administered locally, as an alternative to systemic administration. We administered rituximab intrapericardially in an attempt to control pericardial effusion. We report the case of an 85-year-old woman, diagnosed with marginal zone lymphoma, who developed heart failure due to lymphomatous infiltration of the pericardium. We discuss in detail the possibility of intrapericardial treatment of such patients. The patient received rituximab intrapericardially at a dose of 100 mg in addition to systemic rituximab, cyclophosphamide, vincristine and prednisone immunochemotherapy. The treatment proved to be safe and effective. The patient has remained in good health for more than 3 years at the time of writing. Intrapericardial administration of rituximab may be a valuable therapeutic option for patients with lymphoma that involves the pericardium and heart.
利妥昔单抗联合标准化疗改善了 B 细胞非霍奇金淋巴瘤的治疗效果。在特定情况下，它可以局部给药，作为全身给药的替代方案。我们尝试经心包内给予利妥昔单抗以控制心包积液。我们报告了一例 85 岁女性患者，诊断为边缘区淋巴瘤，由于心包的淋巴瘤浸润导致心力衰竭。我们详细讨论了对这类患者进行心包内治疗的可能性。该患者在心包内给予利妥昔单抗 100mg 剂量，联合全身利妥昔单抗、环磷酰胺、长春新碱和泼尼松免疫化疗。治疗结果安全有效。截至撰写本文时，该患者已健康状况良好超过 3 年。对于累及心包和心脏的淋巴瘤患者，心包内给予利妥昔单抗可能是一种有价值的治疗选择。
